Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Opt Express ; 23(12): 15119-33, 2015 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-26193496

RESUMO

An iterative method for computing the channel capacity of both discrete and continuous input, continuous output channels is proposed. The efficiency of new method is demonstrated in comparison with the classical Blahut - Arimoto algorithm for several known channels. Moreover, we also present a hybrid method combining advantages of both the Blahut - Arimoto algorithm and our iterative approach. The new method is especially efficient for the channels with a priory unknown discrete input alphabet.

2.
Mol Genet Metab ; 102(3): 326-38, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21176882

RESUMO

The Research Challenges in CNS Manifestations of Inborn Errors of Metabolism workshop was designed to address challenges in translating potential therapies for these rare disorders, and to highlight novel therapeutic strategies and innovative approaches to CNS delivery, assessment of effects and directions for the future in the treatment of these diseases. Therapies for the brain in inborn errors represent some of the greatest challenges to translational research due to the special properties of the brain, and of inborn errors themselves. This review covers the proceedings of this workshop as submitted by participants. Scientific, ethical and regulatory issues are discussed, along with ways to measure outcomes and the conduct of clinical trials. Participants included regulatory and funding agencies, clinicians, scientists, industry and advocacy groups.


Assuntos
Pesquisa Biomédica , Sistema Nervoso Central , Erros Inatos do Metabolismo/diagnóstico , Erros Inatos do Metabolismo/terapia , Animais , Pesquisa Biomédica/ética , Pesquisa Biomédica/tendências , Sistema Nervoso Central/patologia , Ensaios Clínicos como Assunto/ética , Humanos , Erros Inatos do Metabolismo/fisiopatologia , Doenças Raras/terapia
3.
Mol Genet Metab Rep ; 22: 100549, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31890590

RESUMO

In neuronopathic Hunter syndrome, neurobehavioral symptoms are known to be serious but have been incompletely described. While families face significant stress stemming from this complex and far-reaching array of symptoms, neither caregiver burden nor the neurobehavioral symptoms have been measured comprehensively. We delineated these neurobehavioral characteristics and their impact on the caregiver using multiple approaches. Methods: As part of the initial phase of developing a Hunter-specific behavioral assessment tool, we used multiple methods to obtain data on patient behaviors and caregiver burden, with the intention of drafting item sets for the tool. We utilized 1) caregiver descriptions from focus groups and individual interviews, 2) observations from video-recorded play of affected children, 3) descriptions from historic chart review, 4) consultation with patient advocacy groups and international experts, 5) reports from a caregiver advisory board, and 6) literature review. Results: Neurobehavioral symptoms were diverse and categorized as focus/attention, impulsivity/heightened activity, sensation seeking, emotional/behavioral function, social interaction, and sleep. A significant reported challenge was susceptibility to misinterpretation of some behaviors as defiant or aggressive, particularly if physical. Caregiver burden involved social isolation, exhaustion, stress, and financial and vocational strain. These new descriptions will aid in developing quantitative measures of change in neurobehavioral symptoms and family burden. These descriptions will be the foundation of a neurobehavioral rating scale, which is very much needed to aid in patient management and assess interventions for individuals with neuronopathic Hunter syndrome.

4.
Bone Marrow Transplant ; 41(6): 531-5, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18037941

RESUMO

Hurler syndrome (mucopolysaccharidosis type I, MPS IH) is characterized by a deficiency of alpha-L-iduronidase resulting in progressive multiorgan dysfunction. We sought to determine whether enzyme replacement therapy (ERT) with iduronidase in the peritransplant period affects outcome of hematopoietic stem cell transplantation (HSCT) for MPS IH. Seven children with MPS IH at a median age of 1.5 years at the time of myeloablative HSCT were eligible. All patients had null mutations in IDUA gene. Iduronidase (0.58 mg/kg per dose) was administered intravenously in 11-14 weekly doses before HSCT and 8 weekly doses after HSCT. The infusions were well tolerated. All patients developed antibodies to iduronidase but all engrafted with >90% donor hematopoiesis. A majority of patients had significant pulmonary complications before ERT and HSCT but all are alive and well with a median follow-up of more than 1 year after HSCT. This suggests that ERT prior to HSCT is unlikely to alter engraftment. In addition, morbidity was acceptable, despite a previous history of pulmonary difficulties that suggested that these patients were high risk for these complications. Therefore, we recommend treatment of MPS IH patients with combination of ERT and HSCT therapy to further investigate its potential to enhance outcomes with HSCT.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Iduronidase/administração & dosagem , Mucopolissacaridose I/terapia , Terapia Combinada , Sobrevivência de Enxerto , Humanos , Iduronidase/sangue , Lactente , Bombas de Infusão , Pneumopatias/etiologia , Mucopolissacaridose I/complicações
5.
Bone Marrow Transplant ; 39(4): 211-5, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17290278

RESUMO

Hematopoietic stem cell transplantation as a treatment for childhood cerebral adrenoleukodystrophy (ALD) has historically only been successful in early disease. As ALD is associated with oxidative damage, we reasoned that adjunctive therapy with an antioxidant agent, N-acetyl-L-cysteine (NAC), may provide protection from rapid neurologic decline in boys with advanced cerebral disease. We report three boys with advanced ALD, whose neurologic status and brain radiographic findings were stabilized by treatment including NAC 8-11 months after hematopoietic stem cell transplantation. These results contrast with previous survival data in cerebral ALD patients who had a similar degree of brain involvement, all of whom died within 1 year of stem cell infusion despite a full donor engraftment. Thus, NAC merits investigation as a therapeutic strategy for patients with advanced ALD as an intervention that could change this lethal disease to a condition amendable to treatment with hematopoietic stem cell transplantation.


Assuntos
Acetilcisteína/uso terapêutico , Adrenoleucodistrofia/complicações , Adrenoleucodistrofia/tratamento farmacológico , Antioxidantes/uso terapêutico , Transplante de Células-Tronco Hematopoéticas , Encefalopatias/etiologia , Criança , Terapia Combinada , Humanos , Estimativa de Kaplan-Meier , Imageamento por Ressonância Magnética , Masculino , Projetos Piloto , Índice de Gravidade de Doença , Resultado do Tratamento
6.
JIMD Rep ; 29: 95-102, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26825088

RESUMO

The long-term cognitive and functional outcomes of children with mucopolysaccharidosis type I (MPS-IH) post-hematopoietic cell transplant (HCT) are not well documented, and the role of genetic and treatment factors in these outcomes has yet to be defined. In this multi-site, international study, we (1) characterize the cognitive and functional status of 47 individuals (ages 2-25, mean of 10.6 years) with MPS-IH who are 1-24 years post HCT (mean = 9 years) and (2) examine contributions of genotype, transplant characteristics, and sociodemographic factors to cognitive ability, adaptive behavior, and quality of life. The overall cognitive ability of our sample was mildly impaired, more than two standard deviations below general population norms. Parent reported adaptive behaviors (i.e., communication, daily living, and motor skills) were similarly impaired with a relative strength in socialization. Quality of life, as reported by parents, fell more than two standard deviations below population norms for physical functioning; however, psychosocial quality of life (emotional well-being) approximated population norms. In linear regression analysis, adjusted for demographic and treatment factors, mutation severity was associated with lower cognitive ability (p = 0.005) and adaptive functioning (p = 0.004), but not parent ratings of children's quality of life. Older age at HCT was associated with poorer physical quality of life (p = 0.002); lower socioeconomic status (p = 0.028) and unrelated bone marrow HCT (p = 0.010) were associated with poorer psychosocial quality of life. Implications for screening and early intervention for children at risk for poorer cognitive and functional outcomes are described.

7.
Neurology ; 44(4): 662-5, 1994 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8164821

RESUMO

Patients with metachromatic leukodystrophy (MLD) of juvenile or adult onset present with behavioral abnormalities. In nine patients, diagnosed between ages 11 and 33 years, behavior and neuropsychological test results disclosed a pattern of dementia combining features associated with both frontal and white matter abnormalities. All the patients had been considered to have a psychiatric disorder prior to the diagnosis of MLD, even though none had any of the cardinal features of schizophrenia or other major psychosis. Early diagnosis of late-onset MLD is important to provide access to appropriate effective therapy.


Assuntos
Demência/etiologia , Leucodistrofia Metacromática/psicologia , Adolescente , Adulto , Comportamento , Criança , Demência/fisiopatologia , Demência/psicologia , Feminino , Humanos , Leucodistrofia Metacromática/diagnóstico , Leucodistrofia Metacromática/fisiopatologia , Imageamento por Ressonância Magnética , Masculino , Sistema Nervoso/fisiopatologia , Testes Neuropsicológicos
8.
Bone Marrow Transplant ; 29(6): 491-6, 2002 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11960268

RESUMO

Hurler syndrome (HS) is an autosomal recessive, inherited metabolic storage disorder due to deficiency of lysosomal alpha-L-iduronidase (IDU) enzyme activity. Untreated patients develop progressive mental retardation and multisystem morbidity with a median life expectancy of 5 years. Allogeneic hematopoietic cell transplantation (HCT) can achieve stabilization and even improvement of intellect, with long-term survival. However, children with HS have an increased incidence of graft failure, usually with concomitant autologous marrow reconstitution. Between 1983 and 2000, 71 Hurler children underwent HCT at the University of Minnesota. Of these 71, 19 (27%) experienced graft failure. We report HCT outcomes in all 11 Hurler patients receiving a second HCT at the University of Minnesota. Median age at second HCT was 25 months (range, 16 to 45 months); median time from first HCT was 8 months (range, 4 to 18.5 months). The conditioning regimen consisted of cyclophosphamide/TBI/ATG (n = 8) or busulfan/cyclophosphamide/ATG (n = 3). The source of bone marrow was an unrelated donor in six, matched sibling in four, and mismatched related in one. Five of the 11 grafts were T cell depleted prior to infusion. Overall, 10 of 11 patients showed donor-derived engraftment, of whom three developed grade 3 to 4 acute GVHD. Five of 11 patients are surviving a median of 25 months (range, 2 months to 12 years) with an overall actuarial survival of 50% (95% CI, 27% to 93%) at 4 years. All five show sustained donor engraftment with normalization of IDU activity levels. Three of five evaluable patients demonstrated stabilization of neuropsychological function after second HCT. Currently, allogeneic donor-derived hematopoiesis provides the only chance for long-term survival and improved quality of life in Hurler patients. While graft failure in Hurler patients requires further investigation, a timely second HCT can be well-tolerated and beneficial.


Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Mucopolissacaridose I/cirurgia , Adolescente , Adulto , Feminino , Doença Enxerto-Hospedeiro/patologia , Humanos , Iduronidase/deficiência , Iduronidase/genética , Iduronidase/metabolismo , Leucócitos/enzimologia , Doadores Vivos , Masculino , Pessoa de Meia-Idade , Mucopolissacaridose I/enzimologia , Mucopolissacaridose I/psicologia , Testes Neuropsicológicos , Análise de Sobrevida , Transplante Homólogo/métodos , Resultado do Tratamento
9.
Cell Transplant ; 4(4): 385-92, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7582569

RESUMO

Treatment and potential cure of lysosomal and peroxisomal diseases, heretofore considered fatal, has become a reality during the past decade. Bone marrow transplantation, (BMT), has provided a method for replacement of the disease-causing enzyme deficiency. Cells derived from the donor marrow continue to provide enzyme indefinitely. Several scores of patients with diseases as diverse as metachromatic leukodystrophy, adrenoleukodystrophy, globoid cell leukodystrophy, Hurler syndrome (MPS I-H), Maroteaux-Lamy (MPS VI) Gaucher disease, and fucosidosis have been successfully treated following long-term engraftment. Central nervous system (CNS) manifestations are also prevented or ameliorated in animal models of these diseases following engraftment from normal donors. The microglial cell system has been considered to be the most likely vehicle for enzyme activity following bone marrow engraftment. Microglia in the mature animal or human are derived from the newly engrafted bone marrow. Graft-v-host disease activation of the microglia is also of importance. This article will summarize some of the pertinent literature relative to the role of microglia in such transplant processes.


Assuntos
Transplante de Medula Óssea/patologia , Sistema Nervoso Central/citologia , Doenças por Armazenamento dos Lisossomos/terapia , Microglia/citologia , Transtornos Peroxissômicos/terapia , Animais , Barreira Hematoencefálica , Células da Medula Óssea , Transplante de Medula Óssea/imunologia , Linhagem da Célula , Movimento Celular , Feminino , Doença Enxerto-Hospedeiro/patologia , Humanos , Masculino , Microglia/enzimologia , Microglia/imunologia , Fagocitose
10.
AJNR Am J Neuroradiol ; 18(10): 1909-14, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9403453

RESUMO

PURPOSE: To determine early signs of disease in patients with childhood-onset cerebral adrenoleukodystrophy (COCALD) with the use of proton MR spectroscopy. METHODS: Eleven children with posterior COCALD involvement and three children with anterior COCALD involvement were studied with single-voxel proton MR spectroscopy and neuropsychological testing. Findings were compared with those in five healthy control subjects. RESULTS: Areas of abnormal T2 signal intensity in children with COCALD showed abnormal metabolite ratios relative to those of control subjects as follows: decreased N-acetylaspartate (NAA)/Creatine (Cr) and NAA/Choline (Ch) and increased Ch/Cr. Metabolite ratios from normal-appearing brain regions in the same patients also were abnormal, with reduced NAA/Cr and NAA/Ch and increased Ch/Cr values. The mean metabolite ratios in normal-appearing regions were between those in the abnormal regions and those found in the control subjects. Statistical comparison of these ratios with neuropsychological test scores, which are specific for anterior and posterior brain functions, showed a significant correlation with the abnormal metabolite ratios. Our results indicate that the normal-appearing brain regions in these patients are metabolically abnormal. CONCLUSION: Proton MR spectroscopy could be a useful noninvasive tool to evaluate extent of disease in patients with COCALD.


Assuntos
Adrenoleucodistrofia/diagnóstico , Encefalopatias Metabólicas/diagnóstico , Metabolismo Energético/fisiologia , Espectroscopia de Ressonância Magnética , Testes Neuropsicológicos , Adolescente , Adrenoleucodistrofia/fisiopatologia , Ácido Aspártico/análogos & derivados , Ácido Aspártico/metabolismo , Encéfalo/fisiopatologia , Encefalopatias Metabólicas/fisiopatologia , Mapeamento Encefálico , Criança , Pré-Escolar , Colina/metabolismo , Estudos de Coortes , Creatina/metabolismo , Feminino , Humanos , Masculino
11.
Med Phys ; 26(11): 2410-4, 1999 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10587225

RESUMO

Current electronic portal imaging devices (EPID) are limited in their ability to provide direct and quick verification and monitoring of patients during both setup and treatment of breathing synchronized radiotherapy (BSRT, including breathing gated, voluntary and forced breath-hold radiotherapy treatment.) These limitations are largely due to their slow image capture rate and poor image quality. An amorphous silicon array flat panel electronic portal imaging device (si-EPID) is emerging to meet the challenge. The purpose of this study is threefold: (1) to characterize the performance of a prototype si-EPID; (2) to compare image quality against that of digitized films; and (3) to evaluate the device in terms of verification of patient setup and monitoring during BSRT. In this study a Varian prototype si-EPID detector array and Clinic accelerator at the University of California Davis Cancer Center were used for imaging. Three quality assurance phantoms: a Lutz PVC phantom, a modified "Las Vegas" phantom, and a RMI model 1151 phantom, were used to characterize the imaging system. A Rando head phantom was used for anthropomorphic imaging tests. Images were obtained with the si-EPID and a Fuji RX film in a Kodak X-Omatic cassette. To investigate the clinical application, two sets of si-EPID images were collected from a lung cancer patient during a 22 s breath-hold and normal breathing. The quality of images obtained with the fast mode was found to be comparable to that obtained with the digitized films. The images with the standard mode were found to be better than the digitized film images. With this prototype si-EPID, it is possible to collect the images at the beginning, middle, and end of each breath-hold for those patients who can hold their breath for longer than 15 s. The si-EPID images can provide a quick verification of the initial patient setup and subsequent treatment position throughout the daily fractionation.


Assuntos
Pulmão/diagnóstico por imagem , Radioterapia/métodos , Respiração , Artefatos , Calibragem , Humanos , Aumento da Imagem/métodos , Neoplasias Pulmonares/radioterapia , Modelos Teóricos , Monitorização Fisiológica , Movimento , Neoplasias Pancreáticas/radioterapia , Imagens de Fantasmas , Postura , Radiografia , Radioterapia/instrumentação , Fatores de Tempo
12.
Pediatr Neurol ; 10(4): 289-94, 1994 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-7520699

RESUMO

The childhood-onset cerebral form of adrenoleukodystrophy has a devastating neurologic prognosis. Unfortunately, there is no early method of distinguishing it from the more benign forms of adrenoleukodystrophy, such as adrenomyeloneuropathy. To evaluate the manner in which this disease entity may be reflected in the cerebrospinal fluid, we studied a consecutive series of 19 patients, all with biochemically proved adrenoleukodystrophy. total protein, immunoglobulin production, cytokine levels, and cerebrospinal fluid pressure were measured. In this single sample of cerebrospinal fluid, a significant correlation existed between clinical stage of the illness and cerebrospinal fluid myelin basic protein. No correlation existed with total protein, cytokines, or measures of immunoglobulin production.


Assuntos
Adrenoleucodistrofia/líquido cefalorraquidiano , Proteínas do Líquido Cefalorraquidiano/análise , Citocinas/líquido cefalorraquidiano , Imunoglobulina G/líquido cefalorraquidiano , Adolescente , Adrenoleucodistrofia/diagnóstico , Pressão do Líquido Cefalorraquidiano , Criança , Pré-Escolar , Diagnóstico Diferencial , Feminino , Humanos , Masculino , Proteína Básica da Mielina/líquido cefalorraquidiano , Prognóstico , Índice de Gravidade de Doença
13.
Bone Marrow Transplant ; 43(1): 21-7, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18776925

RESUMO

Wolman disease is the infantile form of autosomal recessive acid lipase deficiency, typically presenting in early infancy with diarrhea, massive hepatosplenomegaly, failure to thrive, and calcification of adrenal glands. Hematopoietic cell transplantation (HCT) is the only therapy reported to prevent hepatic failure and death, which without treatment occurs within the first year of life. We report a single institution's experience with HCT treatment of four Wolman patients, two of whom are long-term survivors (the longest survival reported to date, (4 and 11 years). Survivors showed resolution of diarrhea within weeks after engraftment, normalized hepatic function, improved hepatosplenomegaly, and in one patient normal adrenal function. The older patient has normal adaptive functions but mild to moderate neurocognitive deficiencies thought to be secondary to treatment and other medical problems. The younger patient has age-appropriate neurodevelopmental and adaptive abilities. We conclude that Wolman disease can be successfully treated with HCT, and that hepatic and cognitive function can be preserved with early diagnosis and timely referral to a transplant center.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Doença de Wolman/terapia , Sistema Endócrino/patologia , Feminino , Trato Gastrointestinal/patologia , Sistema Hematopoético/patologia , Humanos , Lactente , Recém-Nascido , Fígado/patologia , Masculino , Sobreviventes , Doença de Wolman/metabolismo , Doença de Wolman/patologia , Doença de Wolman/psicologia
14.
Neurology ; 64(3): 434-41, 2005 Feb 08.
Artigo em Inglês | MEDLINE | ID: mdl-15699371

RESUMO

BACKGROUND: Early detection of white matter lesions in childhood-onset cerebral adrenoleukodystrophy (ALD) is important as hematopoietic cell transplantation (HCT), currently the only effective treatment, is beneficial only if performed early in the disease course. OBJECTIVE: To establish reliable biochemical markers of cerebral disease progression in patients with ALD to aid in treatment planning. METHODS: The authors used proton magnetic resonance spectroscopy (MRS) in combination with LCModel analysis to quantify brain metabolites in small volumes (3 to 16 mL) in the occipital and frontal white matter and the splenium of the corpus callosum of 17 unsedated patients and 26 healthy volunteers (adult n = 21, age-matched n = 5) at 4 tesla. RESULTS: Absolute concentrations of 12 metabolites were reliably determined, seven of which were established as markers of lesion development. Among these, creatine and choline containing compounds were the weakest markers while N-acetylaspartate, glutamine, and lipids + lactate were the strongest. The large extent of changes in the markers enabled detection of early neurochemical changes in lesion formation prior to detection of abnormalities by conventional MRI. Concentrations of a number of metabolites were also significantly different between normal appearing white matter of patients and controls indicating biochemical alterations in the absence of cerebral disease. Neurochemical improvements following HCT were measured in six patients. CONCLUSIONS: The progression of adrenoleukodystrophy, as well as effectiveness of its treatment, can be assessed with high precision using high field 1H magnetic resonance spectroscopy in individual patients without the need for sedation.


Assuntos
Adrenoleucodistrofia/terapia , Química Encefálica , Espectroscopia de Ressonância Magnética , Adolescente , Adrenoleucodistrofia/classificação , Adrenoleucodistrofia/diagnóstico , Adrenoleucodistrofia/metabolismo , Ácido Aspártico/análogos & derivados , Ácido Aspártico/análise , Criança , Pré-Escolar , Creatina/análise , Progressão da Doença , Seguimentos , Glutamina/análise , Transplante de Células-Tronco Hematopoéticas/mortalidade , Humanos , Inositol/análise , Lactatos/análise , Lipídeos/análise , Espectroscopia de Ressonância Magnética/métodos , Masculino , Testes Neuropsicológicos , Prognóstico
15.
Opt Lett ; 22(20): 1544-6, 1997 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-18188293

RESUMO

We present a theory of chirped breathing pulse propagation in optical transmission systems with strong dispersion management. Fast changes of pulse width and chirp over one period are given by a simple model that is verified by direct numerical simulations. An average pulse evolution in the leading order is described by the nonlinear Schrödinger equation, with additional parabolic potential that can be a trapping (when a grating is used) or a nontrapping (without a grating) type.

16.
Behav Neural Biol ; 43(3): 274-86, 1985 May.
Artigo em Inglês | MEDLINE | ID: mdl-3842250

RESUMO

Normal and hyperthyroid rat pups received intraoral infusions of 0.25% quinine hydrochloride at 8, 10, 12, 14, or 16 days of age. Chin scraping and paw treading, aversive behaviors that adult rats show to quinine, emerged at 12 to 14 days in normal animals and were accelerated in hyperthyroid animals. Once these behaviors emerged, the hyperthyroid pups showed levels of both paw treading and chin scraping that were typical of controls several days older. Hyperthyroid and control pups did not differ in their intake of quinine at ages at which there were marked differences in chin scraping and paw treading. Other types of responses that pups show to aversive stimuli, such as paw treading. Other types of responses were not affected by the thyroid treatment. These findings suggest that the appearance of chin scraping and paw treading at 12-14 days of age in normal animals results from maturation of motor systems underlying these behaviors, and that this maturation can be accelerated by treatment with thyroid hormones.


Assuntos
Aprendizagem da Esquiva/efeitos dos fármacos , Hipertireoidismo/fisiopatologia , Quinina/administração & dosagem , Administração Oral , Fatores Etários , Animais , Cateterismo , Comportamento Alimentar/efeitos dos fármacos , Ratos , Ratos Endogâmicos
17.
Dev Psychobiol ; 19(6): 593-606, 1986 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-3803727

RESUMO

Infant rats from 1 to 15 days of age received oral infusions of various taste solutions, and their intake of and behavioral responses to the infusions were observed. From 1 day of age on, pups responded to strong acid and quinine solutions with certain characteristic aversive responses and suppressed intake (Experiment 1). Although even very young (1- and 3-day-old) pups suppressed their intake of strong quinine and acid solutions, and rejected them by showing certain aversive responses (gaping and forelimb flailing), other components of the adultlike aversion response sequence (chin scraping and paw treading) did not appear until approximately 12 days of age. This suggests that the failure of pups to engage in chin scraping and paw treading prior to 12 days is not due to an inability to detect aversive solutions, but rather may be due to an immaturity in pups younger than 12 days of the neural substrates subserving these aversive responses. The emergence of chin scraping and paw treading to strong acid or quinine solutions was not influenced to any marked extent by either the deprivational state of the pup (Experiment 2a) or the site of the infusion (Experiment 2b).


Assuntos
Paladar/fisiologia , Fatores Etários , Animais , Citratos/farmacologia , Ácido Cítrico , Ingestão de Alimentos , Feminino , Privação de Alimentos , Preferências Alimentares , Ácido Clorídrico/farmacologia , Masculino , Boca/fisiologia , Quinina/farmacologia , Ratos , Ratos Endogâmicos , Sacarose/farmacologia
18.
Opt Lett ; 23(9): 682-4, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-18087309

RESUMO

Soliton propagation in a cascaded dispersion-managed optical amplifier system with zero net dispersion is examined. We present a qualitative physical explanation for the recently discovered fact that a soliton with finite energy can propagate down a fiber line with zero or normal average dispersion. We describe a specific practical system for the main properties of such a soliton, namely, the dependence of the soliton power on the pulse width at chirp-free points and the soliton average energy and width at chirp-free points as functions of the dispersion-allocation (strength of the map) parameter.

19.
J Clin Exp Neuropsychol ; 14(4): 610-24, 1992 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-1356997

RESUMO

A 10-year-old white female who had received a bone marrow transplant (BMT) at 57 months of age as treatment for late infantile onset metachromatic leukodystrophy (MLD), a neurodegenerative autosomal recessive storage disease, showed stabilization of the cognitive degenerative process and demonstrated a partial pattern of cognitive deficits and behavioral abnormalities that has been called NLD (nonverbal learning disabilities) associated with white matter disease. A pattern of good rote memory, reading skills, and concrete language contrasted with poor visual spatial skills, mathematics, and abstract problem solving. She did not show the usual speech prosody and social deficits associated with NLD.


Assuntos
Transplante de Medula Óssea , Encefalopatias/terapia , Leucodistrofia Metacromática/terapia , Encefalopatias/patologia , Encefalopatias/psicologia , Cerebrosídeo Sulfatase/metabolismo , Criança , Cognição , Emoções , Feminino , Humanos , Testes de Inteligência , Leucodistrofia Metacromática/patologia , Leucodistrofia Metacromática/psicologia , Imageamento por Ressonância Magnética , Sistema Nervoso/patologia , Desempenho Psicomotor/fisiologia , Comportamento Social , Tomografia Computadorizada por Raios X , Transplante Homólogo
20.
Curr Opin Neurol ; 12(2): 167-76, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10226749

RESUMO

Over 400 patients with lysosomal and peroxisomal storage diseases have received hematopoietic stem cell transplantation from normal donors. Without treatment, all of these diseases have an inexorable fate leading to central nervous system deterioration and early death. On the other hand, all of the engrafted hosts have had a remarkable positive clinical improvement in response to normalization of previously deficient enzymatic activity. Survival data for those engrafted indicates continued life-span as long as two decades beyond transplantation. The particular diseases treated in this way are included in this article. The specific indications and methods for transplantation are also included in this article.


Assuntos
Transplante de Medula Óssea , Doenças do Sistema Nervoso Central/terapia , Erros Inatos do Metabolismo/terapia , Transplante de Medula Óssea/métodos , Transplante de Medula Óssea/normas , Doenças do Sistema Nervoso Central/etiologia , Humanos , Erros Inatos do Metabolismo/complicações , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA